compound 13 [Chen et al., 2016]   Click here for help

GtoPdb Ligand ID: 9205

Compound class: Synthetic organic
Comment: Compound 13 is reported as a DOT1L inhibitor, with a novel chemical structure, distinct from that of pinometostat (EPZ-5676) [1]. Compound 13 acts as a SAM-competitive inhibitor, binding to an induced pocket adjacent to the SAM binding site.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 94.19
Molecular weight 476.21
XLogP 4.86
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNc1ccnc(n1)Nc1ccc2c(c1)n(c(c2)C)c1ccccc1Oc1cnc2c(c1)ncn2C
Isomeric SMILES CNc1ccnc(n1)Nc1ccc2c(c1)n(c(c2)C)c1ccccc1Oc1cnc2c(c1)ncn2C
InChI InChI=1S/C27H24N8O/c1-17-12-18-8-9-19(32-27-29-11-10-25(28-2)33-27)13-23(18)35(17)22-6-4-5-7-24(22)36-20-14-21-26(30-15-20)34(3)16-31-21/h4-16H,1-3H3,(H2,28,29,32,33)
InChI Key RQVLGMREYUFLPQ-UHFFFAOYSA-N
Bioactivity Comments
Compound 13 exhibits a favourable selectivity profile against a panel of 22 PKMTs and PRMTs with no inhibitory activity up to 50μM [1]. It also suppress H3K79 dimethylation (IC50 16nM) and has a long on-target residence time as assessed by surface plasmon resonance experiments (> 240 minutes). In vitro, compound 13 effectively inhibits proliferation of the human MLL-rearranged leukemia cell line MV4-11 which expresses the oncogenic MLL-AF4 fusion .
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
DOT1 like histone lysine methyltransferase Hs Inhibitor Inhibition 10.1 pKi - 1
pKi 10.1 (Ki 8x10-11 M) [1]
Description: Scintillation proximity assay result